Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jenscare Scientific Co. Ltd. Class H ( (HK:9877) ) has shared an announcement.
Jenscare Scientific reported its first year of commercialization, generating RMB90.6 million in revenue and total income and gains of RMB107.2 million for 2025, while narrowing its adjusted non-IFRS loss to RMB162.4 million and sharply reducing operating cash outflows. The company attributed the improvement to revenue growth, operational efficiency and tighter cost control, as it ramps up sales of its structural heart disease devices.
Commercial progress was highlighted by rapid uptake of its Ken-Valve TAVR product and clinical-commercial breakthroughs for LuX-Valve Plus and JensClip in multiple countries and regions. Global registration for LuX-Valve Plus is accelerating, with a pivotal trial underway in the U.S., CE review and commercialization readiness in Europe, regulatory approval in Australia and New Zealand, smooth NMPA review in China, and early commercial clinical use in the Greater Bay Area, underpinning expectations for sustained international revenue growth and long-term development.
More about Jenscare Scientific Co. Ltd. Class H
Jenscare Scientific Co., Ltd. is a China-based medical device company focused on interventional products for structural heart disease. Its core portfolio includes the Ken-Valve transcatheter aortic valve replacement (TAVR) system, the LuX-Valve Plus transcatheter tricuspid valve replacement (TTVR) product, and the JensClip transcatheter mitral valve repair (TMVr) device, targeting global markets including the U.S., Europe, Australia, China and the Greater Bay Area.
Average Trading Volume: 206,888
Technical Sentiment Signal: Buy
Current Market Cap: HK$5.06B
Find detailed analytics on 9877 stock on TipRanks’ Stock Analysis page.